Market Research Report
Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Drugs In Development, 2021
|Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Drugs In Development, 2021|
Published: December 30, 2021
Global Markets Direct
Content info: 58 Pages
Delivery time: 1-2 business days
According to the recently published report 'Leptin Receptor - Drugs In Development, 2021'; Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) pipeline Target constitutes close to 11 molecules.
Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Leptin receptor or LEP-R is a protein encoded by the LEPR gene. It acts as a receptor for hormone LEP/leptin. Upon binding it mediates LEP central and peripheral effects through the activation of different signaling pathways such as JAK2/STAT3 and MAPK cascade. LEP acts as an appetite-regulating factor that induces a decrease in food intake and an increase in energy consumption by inducing anorexinogenic factors and suppressing orexigenic neuropeptides also regulates bone mass and secretion of hypothalamo-pituitary-adrenal hormones. In the periphery increases basal metabolism, influences reproductive function, regulates pancreatic beta-cell function and insulin secretion, is pro-angiogenic and affects innate and adaptive immunity.
The report 'Leptin Receptor - Drugs In Development, 2021' outlays comprehensive information on the Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II and Preclinical stages are 2 and 9 respectively. Report covers products from therapy areas Metabolic Disorders, Oncology, Central Nervous System and Ophthalmology which include indications Obesity, Lipodystrophy (Lipoatrophy), Triple-Negative Breast Cancer (TNBC), Acquired Generalized Lipodystrophy (Lawrence Syndrome), Alzheimer's Disease, Choroidal Neovascularization, Congenital Generalized Lipodystrophy (Berardinelli-Seip Syndrome), Insulin Resistance, Solid Tumor, Type 1 Diabetes (Juvenile Diabetes) and Type 2 Diabetes.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.